Simcere Pharmaceutical Gets NMPA Approval for Clinical Study of Trispecific Antibody SIM0500
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that it...
Fosun Pharmaceutical Gets NMPA Green Light for Phase I Study of Fibrosis Drug HLX6018
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
NMPA Releases 78th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 78th batch of reference drugs for...
China’s NHC Outlines Cross-departmental Law Enforcement to Strengthen Medical Supervision
The National Health Commission (NHC) has issued a set of “Opinions on Strengthening Cross-departmental Law...
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
Kelun-Biotech’s A400 Receives Fast-Track Status from FDA for RET Fusion-Positive NSCLC
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...
Sinocelltech Gains NMPA Approval for Clinical Study of SCTB35 in B-Cell Non-Hodgkin’s Lymphoma
Sinocelltech Group Ltd (SHA: 688520), based in China, has announced that it has received clearance...
Huadong Medicine Secures NMPA Approval for HDM1005, Targeting Type 2 Diabetes and Obesity
Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that it has received...
Innovent and HutchMed’s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer
China’s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics...
Sanofi’s Amlitelimab Shows Promising Phase IIb Results in Atopic Dermatitis, Potential for 12-Week Dosing
Sanofi (NASDAQ: SNY) announced this week promising results from a Phase IIb study of its...
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and...
Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires
Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer...
J&J’s Tremfya Files for Ulcerative Colitis Indication with FDA, Building on Positive Late-Stage Data
The US Food and Drug Administration (FDA) has accepted an indication extension filing from Johnson...
Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), based in China, has received approval from the U.S. Food...
Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval
Everest Medicines (HKG: 1952), based in China, has announced that its New Drug Application (NDA)...
Lepu Biotechnology’s MRG004A ADC Gains Fast Track Designation for Pancreatic Cancer
Lepu Biotechnology Co., Ltd. (HKG: 2157), based in China, has announced that its in-house developed...
Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval
Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched...